LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Exelixis Inc

Închisă

SectorSănătate

45.34 -1.52

Rezumat

Modificarea prețului

24h

Curent

Minim

45.02

Maxim

46.42

Indicatori cheie

By Trading Economics

Venit

140M

Vânzări

27M

567M

P/E

Medie Sector

20.994

56.602

EPS

0.55

Marjă de profit

24.678

Angajați

1,147

EBITDA

171M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-11.07% downside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

716M

10B

Deschiderea anterioară

46.86

Închiderea anterioară

45.34

Sentimentul știrilor

By Acuity

100%

0%

370 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Exelixis Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 mai 2025, 20:42 UTC

Achiziții, Fuziuni, Preluări

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More -- Barrons.com

Comparație

Modificare preț

Exelixis Inc Așteptări

Obiectiv de preț

By TipRanks

-11.07% jos

Prognoză pe 12 luni

Medie 41.14 USD  -11.07%

Maxim 56 USD

Minim 29 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruExelixis Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

16 ratings

10

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 36.6Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

370 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.